CHD trades 0.3% above Wall Street's consensus target of $109.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CHD achieves its forward estimates and maintains a stable P/E multiple of 28.9x. This scenario reflects the blended consensus of 34 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Church & Dwight Co., Inc. (CHD) has a Wall Street consensus price target of $109.00, based on estimates from 34 covering analysts. With the stock currently trading at $109.33, this represents a potential downside of -0.3%. The company has a market capitalization of $25.91B.
Analyst price targets range from a low of $83.00 to a high of $115.00, representing a 29% spread in expectations. The median target of $113.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,15 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, CHD trades at a trailing P/E of 36.2x and forward P/E of 28.9x. Analysts expect EPS to grow +16.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $130.49, with bear and bull scenarios of $82.21 and $171.93 respectively. Model confidence stands at 55/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PGThe Procter & Gamble Company | $385.2B | $165.40 | $166.78 | +0.8% | Buy | 23.7x | 53 |
 CLColgate-Palmolive Company | $77.3B | $96.56 | $101.00 | +4.6% | Hold | 24.7x | 46 |
 ELThe Estée Lauder Companies Inc. | $39.8B | $110.06 | $109.38 | -0.6% | Buy | 32.1x | 46 |
 KMBKimberly-Clark Corporation | $36.0B | $108.43 | $114.20 | +5.3% | Hold | 14.7x | 32 |
 RCUSArcus Biosciences, Inc. | $2.3B | $18.28 | $38.80 | +112.3% | Buy | — | 18 |
 SPBSpectrum Brands Holdings, Inc. | $2.0B | $86.68 | $97.60 | +12.6% | Buy | 13.6x | 21 |
 ENREnergizer Holdings, Inc. | $1.6B | $23.84 | $19.50 | -18.2% | Hold | 7.2x | 24 |
 COTYCoty Inc. | $3.6B | $4.05 | $2.86 | -29.4% | Hold | 18.8x | 33 |
 EPCEdgewell Personal Care Company | $1.3B | $27.99 | $30.80 | +10.0% | Hold | 14.5x | 17 |
 PBHPrestige Consumer Healthcare Inc. | $2.0B | $42.98 | $81.67 | +90.0% | Buy | 9.4x | 17 |
Quick answers to the most common questions about buying CHD stock.
Wall Street's consensus price target for CHD is $109, -0.3% from its current price of $109.33. The below-market target from 34 analysts suggests limited near-term appreciation.
CHD has a consensus rating of "Buy" based on 34 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $109 implies -0.3% downside from current levels.
CHD trades at a forward P/E of 28.9493x, representing a moderate valuation. With analysts targeting $109 (-0.3% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $115 for CHD, while the most conservative target is $83. The consensus of $109 represents the median expectation. Our quantitative valuation model projects a bull case target of $172 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CHD is heavily covered by Wall Street, with 34 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 15 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CHD stock forecast based on 34 Wall Street analysts shows a consensus price target of $109, with estimates ranging from $83 (bear case) to $115 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $130, with bear/bull scenarios of $82/$172.
Our quantitative valuation model calculates CHD's fair value at $130 (base case), with a bear case of $82 and bull case of $172. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.
CHD trades at a forward P/E ratio of 28.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 36.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on CHD, with 1 Sell ratings and a price target of $109 (-0.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CHD analyst price targets range from $83 to $115, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $109 consensus represents the middle ground. Our model's $82-$172 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.